Does the Use of Peripheral Immune-Related Markers Indicate Whether to Administer Pazopanib, Trabectedin, or Eribulin to Advanced Soft Tissue Sarcoma Patients?

Pazopanib, trabectedin, and eribulin are administered for the treatment of soft tissue sarcomas (STSs); however, there is little consensus on which agent should be preferentially used in a clinical setting. This study assessed whether peripheral immune-related markers served as a useful reference wh...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Eijiro Shimada, Makoto Endo, Yoshihiro Matsumoto, Kenji Tsuchihashi, Mamoru Ito, Hitoshi Kusaba, Akira Nabeshima, Tomoya Nawata, Akira Maekawa, Tomoya Matsunobu, Nokitaka Setsu, Toshifumi Fujiwara, Keiichiro Iida, Makoto Nakagawa, Takeshi Hirose, Masaya Kanahori, Ryunosuke Oyama, Taichi Isobe, Hiroshi Ariyama, Kenichi Kohashi, Hidetaka Yamamoto, Yoshinao Oda, Yukihide Iwamoto, Koichi Akashi, Eishi Baba, Yasuharu Nakashima
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	soft tissue sarcoma chemotherapy pazopanib trabectedin eribulin prognosis Medicine R
Acceso en línea:	https://doaj.org/article/83ef06768c8640f781e5885ec1f589d1
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:83ef06768c8640f781e5885ec1f589d1
record_format	dspace
spelling	oai:doaj.org-article:83ef06768c8640f781e5885ec1f589d12021-11-11T17:36:13ZDoes the Use of Peripheral Immune-Related Markers Indicate Whether to Administer Pazopanib, Trabectedin, or Eribulin to Advanced Soft Tissue Sarcoma Patients?10.3390/jcm102149722077-0383https://doaj.org/article/83ef06768c8640f781e5885ec1f589d12021-10-01T00:00:00Zhttps://www.mdpi.com/2077-0383/10/21/4972https://doaj.org/toc/2077-0383Pazopanib, trabectedin, and eribulin are administered for the treatment of soft tissue sarcomas (STSs); however, there is little consensus on which agent should be preferentially used in a clinical setting. This study assessed whether peripheral immune-related markers served as a useful reference when selecting pazopanib, trabectedin, or eribulin. This study included 63 patients who were administered pazopanib, trabectedin, or eribulin for advanced STSs between March 2015 and December 2020. Patients were divided into three groups based on the first drug administered among these three drugs. Differences in overall survival (OS) or progression-free survival (PFS) among the three groups were analyzed. OS showed no significant differences among the drugs administered first. For patients with low neutrophil-to-lymphocyte ratio (NLR), the OS of patients administered pazopanib as the first choice was shorter than the others (hazard ratio [HR] = 9.53, 95% confidence interval [CI] = 1.94–18.13, <i>p</i> = 0.0018). In the low platelet-to-lymphocyte ratio (PLR) subgroup, the OS of the patients administered eribulin for the first choice was longer than that of the others (HR = 0.32, 95%CI = 0.10–0.98, <i>p</i> = 0.046). Therefore, NLR and PLR might be used as prognostic indicators to dictate whether STS patients receive pazopanib, trabectedin, or eribulin.Eijiro ShimadaMakoto EndoYoshihiro MatsumotoKenji TsuchihashiMamoru ItoHitoshi KusabaAkira NabeshimaTomoya NawataAkira MaekawaTomoya MatsunobuNokitaka SetsuToshifumi FujiwaraKeiichiro IidaMakoto NakagawaTakeshi HiroseMasaya KanahoriRyunosuke OyamaTaichi IsobeHiroshi AriyamaKenichi KohashiHidetaka YamamotoYoshinao OdaYukihide IwamotoKoichi AkashiEishi BabaYasuharu NakashimaMDPI AGarticlesoft tissue sarcomachemotherapypazopanibtrabectedineribulinprognosisMedicineRENJournal of Clinical Medicine, Vol 10, Iss 4972, p 4972 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	soft tissue sarcoma chemotherapy pazopanib trabectedin eribulin prognosis Medicine R
spellingShingle	soft tissue sarcoma chemotherapy pazopanib trabectedin eribulin prognosis Medicine R Eijiro Shimada Makoto Endo Yoshihiro Matsumoto Kenji Tsuchihashi Mamoru Ito Hitoshi Kusaba Akira Nabeshima Tomoya Nawata Akira Maekawa Tomoya Matsunobu Nokitaka Setsu Toshifumi Fujiwara Keiichiro Iida Makoto Nakagawa Takeshi Hirose Masaya Kanahori Ryunosuke Oyama Taichi Isobe Hiroshi Ariyama Kenichi Kohashi Hidetaka Yamamoto Yoshinao Oda Yukihide Iwamoto Koichi Akashi Eishi Baba Yasuharu Nakashima Does the Use of Peripheral Immune-Related Markers Indicate Whether to Administer Pazopanib, Trabectedin, or Eribulin to Advanced Soft Tissue Sarcoma Patients?
description	Pazopanib, trabectedin, and eribulin are administered for the treatment of soft tissue sarcomas (STSs); however, there is little consensus on which agent should be preferentially used in a clinical setting. This study assessed whether peripheral immune-related markers served as a useful reference when selecting pazopanib, trabectedin, or eribulin. This study included 63 patients who were administered pazopanib, trabectedin, or eribulin for advanced STSs between March 2015 and December 2020. Patients were divided into three groups based on the first drug administered among these three drugs. Differences in overall survival (OS) or progression-free survival (PFS) among the three groups were analyzed. OS showed no significant differences among the drugs administered first. For patients with low neutrophil-to-lymphocyte ratio (NLR), the OS of patients administered pazopanib as the first choice was shorter than the others (hazard ratio [HR] = 9.53, 95% confidence interval [CI] = 1.94–18.13, <i>p</i> = 0.0018). In the low platelet-to-lymphocyte ratio (PLR) subgroup, the OS of the patients administered eribulin for the first choice was longer than that of the others (HR = 0.32, 95%CI = 0.10–0.98, <i>p</i> = 0.046). Therefore, NLR and PLR might be used as prognostic indicators to dictate whether STS patients receive pazopanib, trabectedin, or eribulin.
format	article
author	Eijiro Shimada Makoto Endo Yoshihiro Matsumoto Kenji Tsuchihashi Mamoru Ito Hitoshi Kusaba Akira Nabeshima Tomoya Nawata Akira Maekawa Tomoya Matsunobu Nokitaka Setsu Toshifumi Fujiwara Keiichiro Iida Makoto Nakagawa Takeshi Hirose Masaya Kanahori Ryunosuke Oyama Taichi Isobe Hiroshi Ariyama Kenichi Kohashi Hidetaka Yamamoto Yoshinao Oda Yukihide Iwamoto Koichi Akashi Eishi Baba Yasuharu Nakashima
author_facet	Eijiro Shimada Makoto Endo Yoshihiro Matsumoto Kenji Tsuchihashi Mamoru Ito Hitoshi Kusaba Akira Nabeshima Tomoya Nawata Akira Maekawa Tomoya Matsunobu Nokitaka Setsu Toshifumi Fujiwara Keiichiro Iida Makoto Nakagawa Takeshi Hirose Masaya Kanahori Ryunosuke Oyama Taichi Isobe Hiroshi Ariyama Kenichi Kohashi Hidetaka Yamamoto Yoshinao Oda Yukihide Iwamoto Koichi Akashi Eishi Baba Yasuharu Nakashima
author_sort	Eijiro Shimada
title	Does the Use of Peripheral Immune-Related Markers Indicate Whether to Administer Pazopanib, Trabectedin, or Eribulin to Advanced Soft Tissue Sarcoma Patients?
title_short	Does the Use of Peripheral Immune-Related Markers Indicate Whether to Administer Pazopanib, Trabectedin, or Eribulin to Advanced Soft Tissue Sarcoma Patients?
title_full	Does the Use of Peripheral Immune-Related Markers Indicate Whether to Administer Pazopanib, Trabectedin, or Eribulin to Advanced Soft Tissue Sarcoma Patients?
title_fullStr	Does the Use of Peripheral Immune-Related Markers Indicate Whether to Administer Pazopanib, Trabectedin, or Eribulin to Advanced Soft Tissue Sarcoma Patients?
title_full_unstemmed	Does the Use of Peripheral Immune-Related Markers Indicate Whether to Administer Pazopanib, Trabectedin, or Eribulin to Advanced Soft Tissue Sarcoma Patients?
title_sort	does the use of peripheral immune-related markers indicate whether to administer pazopanib, trabectedin, or eribulin to advanced soft tissue sarcoma patients?
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/83ef06768c8640f781e5885ec1f589d1
work_keys_str_mv	AT eijiroshimada doestheuseofperipheralimmunerelatedmarkersindicatewhethertoadministerpazopanibtrabectedinoreribulintoadvancedsofttissuesarcomapatients AT makotoendo doestheuseofperipheralimmunerelatedmarkersindicatewhethertoadministerpazopanibtrabectedinoreribulintoadvancedsofttissuesarcomapatients AT yoshihiromatsumoto doestheuseofperipheralimmunerelatedmarkersindicatewhethertoadministerpazopanibtrabectedinoreribulintoadvancedsofttissuesarcomapatients AT kenjitsuchihashi doestheuseofperipheralimmunerelatedmarkersindicatewhethertoadministerpazopanibtrabectedinoreribulintoadvancedsofttissuesarcomapatients AT mamoruito doestheuseofperipheralimmunerelatedmarkersindicatewhethertoadministerpazopanibtrabectedinoreribulintoadvancedsofttissuesarcomapatients AT hitoshikusaba doestheuseofperipheralimmunerelatedmarkersindicatewhethertoadministerpazopanibtrabectedinoreribulintoadvancedsofttissuesarcomapatients AT akiranabeshima doestheuseofperipheralimmunerelatedmarkersindicatewhethertoadministerpazopanibtrabectedinoreribulintoadvancedsofttissuesarcomapatients AT tomoyanawata doestheuseofperipheralimmunerelatedmarkersindicatewhethertoadministerpazopanibtrabectedinoreribulintoadvancedsofttissuesarcomapatients AT akiramaekawa doestheuseofperipheralimmunerelatedmarkersindicatewhethertoadministerpazopanibtrabectedinoreribulintoadvancedsofttissuesarcomapatients AT tomoyamatsunobu doestheuseofperipheralimmunerelatedmarkersindicatewhethertoadministerpazopanibtrabectedinoreribulintoadvancedsofttissuesarcomapatients AT nokitakasetsu doestheuseofperipheralimmunerelatedmarkersindicatewhethertoadministerpazopanibtrabectedinoreribulintoadvancedsofttissuesarcomapatients AT toshifumifujiwara doestheuseofperipheralimmunerelatedmarkersindicatewhethertoadministerpazopanibtrabectedinoreribulintoadvancedsofttissuesarcomapatients AT keiichiroiida doestheuseofperipheralimmunerelatedmarkersindicatewhethertoadministerpazopanibtrabectedinoreribulintoadvancedsofttissuesarcomapatients AT makotonakagawa doestheuseofperipheralimmunerelatedmarkersindicatewhethertoadministerpazopanibtrabectedinoreribulintoadvancedsofttissuesarcomapatients AT takeshihirose doestheuseofperipheralimmunerelatedmarkersindicatewhethertoadministerpazopanibtrabectedinoreribulintoadvancedsofttissuesarcomapatients AT masayakanahori doestheuseofperipheralimmunerelatedmarkersindicatewhethertoadministerpazopanibtrabectedinoreribulintoadvancedsofttissuesarcomapatients AT ryunosukeoyama doestheuseofperipheralimmunerelatedmarkersindicatewhethertoadministerpazopanibtrabectedinoreribulintoadvancedsofttissuesarcomapatients AT taichiisobe doestheuseofperipheralimmunerelatedmarkersindicatewhethertoadministerpazopanibtrabectedinoreribulintoadvancedsofttissuesarcomapatients AT hiroshiariyama doestheuseofperipheralimmunerelatedmarkersindicatewhethertoadministerpazopanibtrabectedinoreribulintoadvancedsofttissuesarcomapatients AT kenichikohashi doestheuseofperipheralimmunerelatedmarkersindicatewhethertoadministerpazopanibtrabectedinoreribulintoadvancedsofttissuesarcomapatients AT hidetakayamamoto doestheuseofperipheralimmunerelatedmarkersindicatewhethertoadministerpazopanibtrabectedinoreribulintoadvancedsofttissuesarcomapatients AT yoshinaooda doestheuseofperipheralimmunerelatedmarkersindicatewhethertoadministerpazopanibtrabectedinoreribulintoadvancedsofttissuesarcomapatients AT yukihideiwamoto doestheuseofperipheralimmunerelatedmarkersindicatewhethertoadministerpazopanibtrabectedinoreribulintoadvancedsofttissuesarcomapatients AT koichiakashi doestheuseofperipheralimmunerelatedmarkersindicatewhethertoadministerpazopanibtrabectedinoreribulintoadvancedsofttissuesarcomapatients AT eishibaba doestheuseofperipheralimmunerelatedmarkersindicatewhethertoadministerpazopanibtrabectedinoreribulintoadvancedsofttissuesarcomapatients AT yasuharunakashima doestheuseofperipheralimmunerelatedmarkersindicatewhethertoadministerpazopanibtrabectedinoreribulintoadvancedsofttissuesarcomapatients
_version_	1718432073043148800

Does the Use of Peripheral Immune-Related Markers Indicate Whether to Administer Pazopanib, Trabectedin, or Eribulin to Advanced Soft Tissue Sarcoma Patients?

Ejemplares similares